ROIV Stock Recent News

Roivant Sciences operates with an innovative business model through its subsidiaries, specializing in specific therapeutic areas such as immuno-dermatology and autoimmune disorders. Notable achievements include the sale of Telavant to Roche, the successful performance of Vtama cream for psoriasis, and advancements in clinical trials for atopic dermatitis and IMVT-1402 antibody development. Despite the lack of immediate catalysts and ongoing cash burn, the stock trades at a substantial discount relative to its sector, making it a "buy" at current levels.

Roivant Sciences stock moved lower on Monday after the biopharmaceutical company announced that its lupus therapeutic oral brepocitinib failed to meet the primary endpoint in a Phase 2 study. The company said it plans to continue progressing the drug in other indications outside of Systemic Lupus Erythematosus (SLE) given its favorable safety and tolerability profile, six other positive Phase 2 studies, and the active arm performance of this study.

Roivant Sciences Ltd. shares ROIV fell 3% premarket on Monday after the company said the experimental treatment brepocitinib failed to meet its main goal in a trial involving patients with moderate to severe lupus.

Roivant Sciences said on Monday its experimental drug to treat autoimmune disease systemic lupus erythematosus (SLE) failed to meet the main goal of reducing symptoms in a mid-stage study.

BASEL, LONDON, and NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 13, 2023, to report its financial results for the second quarter ended September 30, 2023, and provide a business update.

Roche Holding AG acquires Telavant Holdings for $7.1B upfront and $150M milestone payment, potentially very interesting deal. Roivant Sciences owns a 75% equity interest in Telavant Holdings. Curiously, Roivant Sciences stock sold off on the news.

Monday, Roivant Sciences announced an asset sale to Roche. The biotech is slated to earn $5.2 billion upon closing, plus a $110 milestone payment once a late-stage trial commences.

Third-quarter earnings season has only just begun and Morgan Stanley's pessimistic market strategist Mike Wilson is already labelling it a disappointment.

October has typically been a solid month for stocks. CRISPR Therapeutics, DraftKings, and Roivant Sciences are three growth stocks that screen as top buys right now.

Roivant Sciences Ltd. (ROIV) saw its shares surge in the last session with trading volume being higher than average.